Discover groundbreaking insights from the 2025 Alzheimer’s Association International Conference, featuring expert interviews on innovative treatments...

Novartis revealed promising phase 3 trial results for ianalumab, a potential first treatment for Sjögren’s disease, showing significant disease activi...

Sam Gandy, MD, PhD, director of the Center for Cognitive Health at the Icahn School of Medicine at Mount Sinai, discussed his presentation on detectin...

The cofounder and chief science officer of the Alzheimer's Drug Discovery Foundation recapped some of the notable recent developments in the Alzheimer...

Panelists discuss how approximately 20% to 30% of patients compliant with CPAP therapy still experience pathological sleepiness, requiring clinicians...

Panelists discuss how FDA-approved medications like modafinil, armodafinil, and solriamfetol serve both therapeutic and diagnostic purposes in treatin...

A recent meta-analysis reveals genistein's potential to enhance cognitive function in prodromal Alzheimer, urging further research for validation.

The Harold I. Nemuth Chair in Neurological Disorders at Virginia Commonwealth University detailed published findings on GLP-1 receptor agonists signif...

New findings highlight the potential of sCD83 as a prognostic biomarker in NMOSD and MOGAD, supporting its role as both a therapeutic target and a mar...

Catch up on any of the neurology news headlines you may have missed over the course of July 2025, compiled all into 1 place by the NeurologyLive® team...